sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com
Summary of Product Characteristics last updated on the eMC: 06/11/2009
SPC Ditropan Elixir 2.5mg/5ml

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/11/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Date of revision of text on the SPC:   01-Oct-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.5 - clozapine added
Updated on 07/04/2009 and displayed until 06/11/2009
Reasons for adding or updating:
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 8: Change to Marketing Authorisation Number: PL04425/0286
Section 9: Date of Renewal of Authorisation: 6 Febraury 2009
Section 10: Date of Revision of text: February 2009
Updated on 18/09/2007 and displayed until 07/04/2009
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   10/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 (market Authorisation Holder): change to sanofi-aventis.
Updated on 19/09/2006 and displayed until 18/09/2007
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   03/2004
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 (Marketing Authorisation Holder): Change to MA Holder's address
Updated on 04/04/2005 and displayed until 19/09/2006
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Updated on 04/08/2004 and displayed until 04/04/2005
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Updated on 26/09/2002 and displayed until 04/08/2004
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Updated on 23/08/2001 and displayed until 26/09/2002
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder

Active Ingredients/Generics

 
   oxybutynin hydrochloride


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk